Acessibilidade / Reportar erro

Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere

Abstract

Living with chronic kidney disease (CKD) is associated with hardships for patients and their care-partners. Empowering patients and their care-partners, including family members or friends involved in their care, may help minimize burden and consequences of CKD-related symptoms to enable life participation. There is a need to broaden the focus on living well with kidney disease and re-engagement in life, including emphasis on patients being in control. The World Kidney Day (WKD) Joint Steering Committee has declared 2021 the year of “Living Well with Kidney Disease” in an effort to increase education and awareness on the important goal of patient empowerment and life participation. This calls for the development and implementation of validated patient-reported outcome measures to assess and address areas of life participation in routine care. It could be supported by regulatory agencies as a metric for quality care or to support labelling claims for medicines and devices. Funding agencies could establish targeted calls for research that address the priorities of patients. Patients with kidney disease and their care-partners should feel supported to live well through concerted efforts by kidney care communities including during pandemics. In the overall wellness program for kidney disease patients, the need for prevention should be reiterated. Early detection with prolonged course of wellness despite kidney disease, after effective secondary and tertiary prevention programs, should be promoted. WKD 2021 continues to call for increased awareness of the importance of preventive measures throughout populations, professionals, and policy makers, applicable to both developed and developing countries.

Patient empowerment; Care-partner; Low-middle-income countries; Health policy


Patient priorities for living well: a focus on life participation

Chronic kidney disease (CKD), its associated symptoms, and its treatment, including medications, dietary and fluid restrictions, and kidney replacement therapy, can disrupt and constrain daily living and impair the overall quality of life of patients and their family members. Consequently, this can also impact on treatment satisfaction and clinical outcomes (11. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int 2018; 94: 1053–1068, doi: 10.1016/j.kint.2018.08.018.
https://doi.org/10.1016/j.kint.2018.08.0...
). Despite this, the past several decades have seen limited improvement in the quality of life of people with CKD (11. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int 2018; 94: 1053–1068, doi: 10.1016/j.kint.2018.08.018.
https://doi.org/10.1016/j.kint.2018.08.0...
). To advance research, practice, and policy, there is an increasing recognition of the need to identify and address patient priorities, values, and goals (11. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int 2018; 94: 1053–1068, doi: 10.1016/j.kint.2018.08.018.
https://doi.org/10.1016/j.kint.2018.08.0...
).

Several regional and global kidney health projects have addressed these important questions including the Standardised Outcomes in Nephrology (SONG) with more than 9,000 patients, family members, and health professionals from over 70 countries (22. Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, et al. Identifying outcomes important to patients with glomerular disease and their caregivers. Clin J Am Soc Nephrol 2020; 15: 673–684, doi: 10.2215/CJN.13101019.
https://doi.org/10.2215/CJN.13101019...
,33. Hanson CS, Craig JC, Logeman C, Sinha A, Dart A, Eddy AA, et al. Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops. Kidney Int 2020; 98: 553–565, doi: 10.1016/j.kint.2020.05.054.
https://doi.org/10.1016/j.kint.2020.05.0...
). Across all treatment stages, including CKD, dialysis, and transplantation, SONG participating children and adults with CKD consistently give higher priority to symptoms and life impacts than health professionals (22. Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, et al. Identifying outcomes important to patients with glomerular disease and their caregivers. Clin J Am Soc Nephrol 2020; 15: 673–684, doi: 10.2215/CJN.13101019.
https://doi.org/10.2215/CJN.13101019...
,33. Hanson CS, Craig JC, Logeman C, Sinha A, Dart A, Eddy AA, et al. Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops. Kidney Int 2020; 98: 553–565, doi: 10.1016/j.kint.2020.05.054.
https://doi.org/10.1016/j.kint.2020.05.0...
). In comparison, health professionals give higher priority to mortality and hospitalization than patients and family members. The patient-prioritized outcomes are shown in Figure 1. Irrespective of the type of kidney disease or treatment stage, patients want to be able to live well, maintain their role and social functioning, protect some semblance of normality, and have a sense of control over their health and wellbeing.

Figure 1
Conceptual framework of “Living Well with Kidney Disease” based on patient centeredness and empowering patients with focus on effective symptom management and life participation.

Life participation, defined as the ability to do meaningful activities of life including, but not limited to work, study, family responsibilities, travel, sports, social and recreational activities, was established as a critically important outcome across all treatment stages of CKD (11. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int 2018; 94: 1053–1068, doi: 10.1016/j.kint.2018.08.018.
https://doi.org/10.1016/j.kint.2018.08.0...
,22. Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, et al. Identifying outcomes important to patients with glomerular disease and their caregivers. Clin J Am Soc Nephrol 2020; 15: 673–684, doi: 10.2215/CJN.13101019.
https://doi.org/10.2215/CJN.13101019...
). The quotations from patients with kidney disease provided in Table 1 demonstrate how life participation reflects the ability to live well with CKD (44. Gonzalez AM, Gutman T, Lopez-Vargas P, Anumudu S, Arce CM, Craig JC, et al. Patient and caregiver priorities for outcomes in CKD: a multinational nominal group technique study. Am J Kid Dis 2020; 76: 679–689, doi: 10.1053/j.ajkd.2020.03.022.
https://doi.org/10.1053/j.ajkd.2020.03.0...
). According to the World Health Organization (WHO), participation refers to “involvement in a life situation” (55. WHO. Towards a common language for functioning, disability and health. 2002; WHO/EIP/GPE/CAS/01.3.). This concept is more specific than the broader construct of quality of life. Life participation places the life priorities and values of those affected by CKD and their family at the center of decision making. The World Kidney Day Steering Committee calls for the inclusion of life participation, a key focus in the care of patients with CKD, to achieve the ultimate goal of living well with kidney disease. This calls for the development and implementation of validated patient-reported outcome measures that could be used to assess and address areas of life participation in routine care. Monitoring of life participation could be supported by regulatory agencies as a metric for quality care or to support labelling claims for medicines and devices. Funding agencies could establish targeted calls for research that addresses the priorities of patients, including life participation.

Table 1
Quotations from patients with chronic kidney disease (CKD) related to priorities for living well.

Patient empowerment, partnership, and a paradigm shift towards a strengths-based approach to care

Patients with CKD and their family members including care-partners should be empowered to achieve the health outcomes and life goals that are meaningful and important to them. The WHO defines patient empowerment as “a process through which people gain greater control over decisions or actions affecting their health” (66. WHO. Health Promotion Glossary. 1998; WHO/HPR/HEP/98.1.), which requires patients to understand their role, to have knowledge to be able to engage with clinicians in shared decision-making, skills, and support for self-management. For patients receiving dialysis, understanding the rationale for lifestyle change, having access to practical assistance, and family support-promoted patient empowerment, while feeling limited in life participation undermines their sense of empowerment (77. Baumgart A, Manera KE, Johnson DW, Craig JC, Shen JI, Ruiz L, et al. Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrol Dial Transplant 2020; 35: 1949–1958, doi: 10.1093/ndt/gfaa127.
https://doi.org/10.1093/ndt/gfaa127...
).

The World Kidney Day Steering Committee advocates for strengthened partnership with patients in the development, implementation, and evaluation of interventions for practice and policy settings that enable patients to live well with kidney diseases. This needs to be supported by consistent, accessible, and meaningful communication. Meaningful involvement of patients and family members across the entire research process, from priority setting and planning the study through dissemination and implementation, is now widely advocated (88. PCORI. The Value of Engagement (Available at https://www.pcori.org/about-us/our-programs/engagement/public-and-patient-engagement/value-engagement, accessed September 1, 2020). 2018.
https://www.pcori.org/about-us/our-progr...
). There have also been efforts, such as the Kidney Health Initiative, to involve patients in the development of drugs and devices to foster innovation (99. Bonventre JV, Hurst FP, West M, Wu I, Roy-Chaudhury P, Sheldon M. A technology roadmap for innovative approaches to kidney replacement therapies: a catalyst for change. Clin J Am Soc Nephrol 2019; 14: 1539–1547, doi: 10.2215/CJN.02570319.
https://doi.org/10.2215/CJN.02570319...
).

We urge for greater emphasis on a strengths-based approach as outlined in Table 2, which encompasses strategies to support patient resilience, harness social connections, build patient awareness and knowledge, facilitate access to support, and establish confidence and control in self-management. The strengths-based approach is in contrast to the medical model where chronic disease is traditionally focused on pathology, problems, and failures (1010. Ibrahim N, Michail M, Callaghan P. The strengths based approach as a service delivery model for severe mental illness: a meta-analysis of clinical trials. BMC Psychiatry 2014; 14: 243, doi: 10.1186/s12888-014-0243-6.
https://doi.org/10.1186/s12888-014-0243-...
). Instead, the strengths-based approach acknowledges that each individual has strengths and abilities to overcome the problems and challenges faced, and requires collaboration and cultivation of the patient's hopes, aspirations, interests, and values. Efforts are needed to ensure that structural biases, discrimination, and disparities in the health care system also be identified, so all patients are given the opportunity to have a voice.

Table 2
Suggested strategies for “living well with CKD” using a strengths-based approach.

The role of the care-partner

A care-partner is often an informal caregiver who is also a family member of the patient with CKD (1111. Parham R, Jacyna N, Hothi D, Marks SD, Holttum S, Camic P. Development of a measure of caregiver burden in paediatric chronic kidney disease: The Paediatric Renal Caregiver Burden Scale. J Health Psychol 2016; 21: 193–205, doi: 10.1177/1359105314524971.
https://doi.org/10.1177/1359105314524971...
). They may take on a wide range of responsibilities including coordinating care (including transportation to appointments), administration of treatment including medications, home dialysis assistance, and supporting dietary management. Caregivers of patients with CKD have reported depression, fatigue, isolation, and also burnout. The role of the care-partner has increasingly become more important in CKD care given the heightened complexity in communicative and therapeutic options including expansion of telemedicine under the COVID-19 pandemic and given the goal to achieve higher life expectancy with CKD (1212. Subramanian L, Kirk R, Cuttitta T, Bryant N, Fox K, McCall M, et al. Remote management for peritoneal dialysis: a qualitative study of patient, care partner, and clinician perceptions and priorities in the United States and the United Kingdom. Kidney Med 2019; 1(6): 354–365, doi: 10.1016/j.xkme.2019.07.014.
https://doi.org/10.1016/j.xkme.2019.07.0...
). The experience of caring for a partially incapacitated family member with progressive CKD can represent a substantial burden on the care-partner and may impact family dynamics. Not infrequently, the career goals and other occupational and leisure aspects of the life of the care-partner are affected because of CKD care partnership, leading to care-partner overload and burnout. Hence, the above-mentioned principles of life participation need to equally apply to care-partners as well as all family members and friends involved in the CKD care.

Living with kidney disease in low income regions

In low and lower-middle income countries (LICs and LMICs) including in sub-Saharan Africa, South East Asia, and Latin America, patients' ability to self-manage or cope with chronic disease varies but may often be influenced by internal factors including spirituality, belief system, and religiosity, and external factors including appropriate knowledge of the disease, poverty, family support system, and one's grit and social relations network. The support system comprising healthcare providers and caregivers plays a crucial role as most patients rely on them in making decisions, and for the necessary adjustments in their health behavior (1313. Angwenyi V, Aantjes C, Kajumi M, De Man J, Criel B, Bunders-Aelen J. Patients experiences of self-management and strategies for dealing with chronic conditions in rural Malawi. PLoS One 2018; 13: e0199977, doi: 10.1371/journal.pone.0199977.
https://doi.org/10.1371/journal.pone.019...
). In LICs, where there are often a relatively low number of physicians and even lower number of kidney care providers per population especially in rural areas, a stepwise approach can involve local and national stakeholders including both non-governmental organizations and government agencies by: 1) extending kidney patient education in rural areas; 2) adapting telehealth technologies if feasible to educate patients and train local community kidney care providers; and 3) implementing effective retention strategies for rural kidney health providers including adapting career plans and competitive incentives.

Many patients in low resource settings present in very late stage needing to commence emergency dialysis (1414. Ulasi II, Ijoma CK. The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria. J Trop Med 2010; 2010: 501957, doi: 10.1155/2010/501957.
https://doi.org/10.1155/2010/501957...
). The very few fortunate ones to receive kidney transplantation may acquire an indescribable chance to normal life again, notwithstanding the high costs of immunosuppressive medications in some countries. For some patients and care-partners in low income regions, spirituality and religiosity may engender hope, when they are energized by the anticipation of restored health and spiritual wellbeing. For many patients, informing them of a diagnosis of kidney disease is a harrowing experience both for the patient (and caregivers) and the healthcare professional. Most patients present to kidney physicians (usually known as “renal physicians” in many of these countries) with trepidations and apprehension. It is rewarding therefore to see the patient's anxiety dissipate after reassuring him or her of a diagnosis of simple kidney cysts, urinary tract infection, simple kidney stones, solitary kidneys, etc., that would not require extreme measures like kidney replacement therapy. Patients diagnosed with glomerulonephritis who have appropriate characterization of their disease from kidney biopsies and histology, receive appropriate therapies, and achieve remission are relieved and very grateful. Patients are glad to discontinue dialysis following resolution of acute kidney injury (AKI) or acute on CKD.

Many CKD patients who have residual kidney function appreciate being maintained in a relatively healthy state with conservative measures, without dialysis. They experience renewed energy when their anemia is promptly corrected using erythropoiesis-stimulating agents. They are happy when their peripheral edema resolves with treatment. For those on maintenance hemodialysis who had woeful stories from emergency femoral cannulations, they appreciate construction of good temporary or permanent vascular accesses. Many patients in low resource settings present in a very late stage needing to commence emergency dialysis. Patients remain grateful on waking from uremic coma or recovering from recurrent seizures when they commence dialysis.

World Kidney Day 2021 advocacy

The World Kidney Day 2021 theme of ‘Living Well with Kidney Disease' is deliberately chosen to have the goals to redirect more focus on plans and actions towards achieving patient-centered wellness. “Kidney Health for Everyone, Everywhere” with emphasis on patient-centered wellness should be a policy imperative that can be successfully achieved if policy makers, nephrologists, health care professionals, patients, and care-partners place this within the context of comprehensive care.

Patient engagement is a requirement. The WHO in 2016 put out an important document on patient empowerment (1515. WHO. Patient Engagement: Technical Series on Safer Primary Care.Geneva, 2016. https://apps.who.int/iris/bitstream/handle/10665/252269/9789241511629-eng.pdf (last accessed January 8, 2021).
https://apps.who.int/iris/bitstream/hand...
): ‘Patient engagement is increasingly recognized as an integral part of health care and a critical component of safe people-centered services. Engaged patients are better able to make informed decisions about their care options. In addition, resources may be better used if they are aligned with patients' priorities and this is critical for the sustainability of health systems worldwide. Patient engagement may also promote mutual accountability and understanding between the patients and health care providers. Informed patients are more likely to feel confident to report both positive and negative experiences and have increased concordance with mutually agreed care management plans. This not only improves health outcomes, but also advances learning and improvement, while reducing adverse events. In the ISN Community Film Event at World Congress of Nephrology (WCN) 20 (ISN Community Film Event 2020), it is good to see a quote in the film from patients: “Tell me, I will forget. Show me, I will remember. Involve me, I will understand” (1616. The 2020 ISN Community Film Event: Share Your Kidney Care Story. https://www.theisn.org/in-action/events/community-film-event/ (last accessed January 8, 2021).
https://www.theisn.org/in-action/events/...
). ISN Global Kidney Policy Forum 2019 included a patient speaker Nicki Scholes-Robertson from New Zealand: ‘Culturally appropriate and sensitive patient information and care are being undertaken in New Zealand to fight inequities in kidney health, especially in Maori and other disadvantaged communities'.

World Kidney Day 2021 would like to encourage policy makers on increasing focus and resources on both drug and non-drug programs in improving patient wellness. Examples include funding for erythropoiesis-stimulating agents and anti-pruritic agents for managing anemia and itchiness, respectively, just to name but a few (1717. Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ 2019; 22: 593–604, doi: 10.1080/13696998.2019.1588738.
https://doi.org/10.1080/13696998.2019.15...
,1818. Sukul N, Speyer E, Tu C, Bieber BA, Li Y, Lopes AA, et al. Pruritus and patient reported outcomes in non-dialysis CKD. Clin J Am Soc Nephrol 2019; 14: 673–681, doi: 10.2215/CJN.09600818.
https://doi.org/10.2215/CJN.09600818...
). Home dialysis therapies have been consistently found to improve patient autonomy, flexibility, and quality of life in a cost-effective manner, enhancing life participation. Promoting home dialysis therapies should tie in with appropriate ‘assisted dialysis' programs to reduce patient and care-partner fatigue and burnout. Also examples like self-management programs, cognitive behavioral therapy, and group therapies for managing depression, anxiety, and insomnia should be promoted before resorting to medications (1919. Gregg LP, Hedayati SS. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Curr Opin Nephrol Hypertens 2020; 29: 457–464, doi: 10.1097/MNH.0000000000000629.
https://doi.org/10.1097/MNH.000000000000...
). The principle of equity recognizes that different people with different levels of disadvantage require different approaches and resources to achieve equitable health outcomes. The kidney community should push for adapted care guidelines for vulnerable and disadvantaged populations. Involvement of primary care and general physicians especially in LICs and LMICs would be useful in improving the affordability and access to services through the public sector in helping symptom management of CKD patients and improve their wellness. In the overall wellness program for kidney disease patients, the need for prevention should be reiterated. Early detection with prolonged course of wellness despite kidney disease, after effective secondary prevention program, should be promoted (2020. Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Kidney Int 2020; 97: 226–232, doi: 10.1016/j.kint.2019.12.002.
https://doi.org/10.1016/j.kint.2019.12.0...
). Prevention of CKD progression can be attempted by lifestyle and diet modifications such as a plant-dominant low protein diet and by means of effective pharmacotherapy including administration of sodium-glucose transport protein 2 (SGLT2) inhibitors (2121. Kalantar-Zadeh K, Li PK. Strategies to prevent kidney disease and its progression. Nat Rev Nephrol 2020; 16: 129–130, doi: 10.1038/s41581-020-0253-1.
https://doi.org/10.1038/s41581-020-0253-...
). World Kidney Day 2021 continues to call for increased awareness of the importance of preventive measures throughout populations, professionals, and policy makers, applicable to both developed and developing countries (2020. Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Kidney Int 2020; 97: 226–232, doi: 10.1016/j.kint.2019.12.002.
https://doi.org/10.1016/j.kint.2019.12.0...
).

Conclusions

Effective strategies to empower patients and their care-partners strive to pursue the overarching goal of minimizing burden of CKD-related symptoms in order to enhance patient satisfaction, health-related quality of life, and life participation. World Kidney Day 2021 theme on “Living Well with Kidney Disease” is deliberately chosen to have the goals to redirect more focus on plans and actions towards achieving patient-centered wellness. Notwithstanding the COVID-19 pandemic that has overshadowed many activities in 2020 and beyond, the World Kidney Day Steering Committee has declared 2021 the year of “Living well with Kidney Disease” in an effort to increase education and awareness on the important goal of effective symptom management and patient empowerment. Whereas the World Kidney Day continues to emphasize the importance of effective measures to prevent kidney disease and its progression (2020. Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Kidney Int 2020; 97: 226–232, doi: 10.1016/j.kint.2019.12.002.
https://doi.org/10.1016/j.kint.2019.12.0...
), patients with preexisting kidney disease and their care-partners should feel supported to live well through concerted efforts by kidney care communities and other stakeholders throughout the world even during a world shattering pandemic as COVID-19 that may drain many resources (2222. Kalantar-Zadeh K, Wightman A, Liao S. Ensuring choice for people with kidney failure - dialysis, supportive care, and hope. N Engl J Med 2020; 383: 99–101, doi: 10.1056/NEJMp2001794.
https://doi.org/10.1056/NEJMp2001794...
). Living well with kidney disease is an uncompromisable goal of all kidney foundations, patient groups, and professional societies alike, to which the International Society of Nephrology and the International Federation of Kidney Foundation World Kidney Alliance are committed at all times.

Acknowledgments

K.K.-Zadeh reports honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, BBraun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. P.K-T. Li reports personal fees from Fibrogen and Astra-Zeneca. G. Saadi reports peronal fees from Multicare, Novartis, Sandoz, and Astra-Zeneca. V. Liakopoulos reports nonfinancial support from Genesis Pharma.

References

  • 1
    Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, et al. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int 2018; 94: 1053–1068, doi: 10.1016/j.kint.2018.08.018.
    » https://doi.org/10.1016/j.kint.2018.08.018
  • 2
    Carter SA, Gutman T, Logeman C, Cattran D, Lightstone L, Bagga A, et al. Identifying outcomes important to patients with glomerular disease and their caregivers. Clin J Am Soc Nephrol 2020; 15: 673–684, doi: 10.2215/CJN.13101019.
    » https://doi.org/10.2215/CJN.13101019
  • 3
    Hanson CS, Craig JC, Logeman C, Sinha A, Dart A, Eddy AA, et al. Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops. Kidney Int 2020; 98: 553–565, doi: 10.1016/j.kint.2020.05.054.
    » https://doi.org/10.1016/j.kint.2020.05.054
  • 4
    Gonzalez AM, Gutman T, Lopez-Vargas P, Anumudu S, Arce CM, Craig JC, et al. Patient and caregiver priorities for outcomes in CKD: a multinational nominal group technique study. Am J Kid Dis 2020; 76: 679–689, doi: 10.1053/j.ajkd.2020.03.022.
    » https://doi.org/10.1053/j.ajkd.2020.03.022
  • 5
    WHO. Towards a common language for functioning, disability and health. 2002; WHO/EIP/GPE/CAS/01.3.
  • 6
    WHO. Health Promotion Glossary. 1998; WHO/HPR/HEP/98.1.
  • 7
    Baumgart A, Manera KE, Johnson DW, Craig JC, Shen JI, Ruiz L, et al. Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. Nephrol Dial Transplant 2020; 35: 1949–1958, doi: 10.1093/ndt/gfaa127.
    » https://doi.org/10.1093/ndt/gfaa127
  • 8
    PCORI. The Value of Engagement (Available at https://www.pcori.org/about-us/our-programs/engagement/public-and-patient-engagement/value-engagement, accessed September 1, 2020). 2018.
    » https://www.pcori.org/about-us/our-programs/engagement/public-and-patient-engagement/value-engagement
  • 9
    Bonventre JV, Hurst FP, West M, Wu I, Roy-Chaudhury P, Sheldon M. A technology roadmap for innovative approaches to kidney replacement therapies: a catalyst for change. Clin J Am Soc Nephrol 2019; 14: 1539–1547, doi: 10.2215/CJN.02570319.
    » https://doi.org/10.2215/CJN.02570319
  • 10
    Ibrahim N, Michail M, Callaghan P. The strengths based approach as a service delivery model for severe mental illness: a meta-analysis of clinical trials. BMC Psychiatry 2014; 14: 243, doi: 10.1186/s12888-014-0243-6.
    » https://doi.org/10.1186/s12888-014-0243-6
  • 11
    Parham R, Jacyna N, Hothi D, Marks SD, Holttum S, Camic P. Development of a measure of caregiver burden in paediatric chronic kidney disease: The Paediatric Renal Caregiver Burden Scale. J Health Psychol 2016; 21: 193–205, doi: 10.1177/1359105314524971.
    » https://doi.org/10.1177/1359105314524971
  • 12
    Subramanian L, Kirk R, Cuttitta T, Bryant N, Fox K, McCall M, et al. Remote management for peritoneal dialysis: a qualitative study of patient, care partner, and clinician perceptions and priorities in the United States and the United Kingdom. Kidney Med 2019; 1(6): 354–365, doi: 10.1016/j.xkme.2019.07.014.
    » https://doi.org/10.1016/j.xkme.2019.07.014
  • 13
    Angwenyi V, Aantjes C, Kajumi M, De Man J, Criel B, Bunders-Aelen J. Patients experiences of self-management and strategies for dealing with chronic conditions in rural Malawi. PLoS One 2018; 13: e0199977, doi: 10.1371/journal.pone.0199977.
    » https://doi.org/10.1371/journal.pone.0199977
  • 14
    Ulasi II, Ijoma CK. The enormity of chronic kidney disease in Nigeria: the situation in a teaching hospital in South-East Nigeria. J Trop Med 2010; 2010: 501957, doi: 10.1155/2010/501957.
    » https://doi.org/10.1155/2010/501957
  • 15
    WHO. Patient Engagement: Technical Series on Safer Primary Care.Geneva, 2016. https://apps.who.int/iris/bitstream/handle/10665/252269/9789241511629-eng.pdf (last accessed January 8, 2021).
    » https://apps.who.int/iris/bitstream/handle/10665/252269/9789241511629-eng.pdf
  • 16
    The 2020 ISN Community Film Event: Share Your Kidney Care Story. https://www.theisn.org/in-action/events/community-film-event/ (last accessed January 8, 2021).
    » https://www.theisn.org/in-action/events/community-film-event/
  • 17
    Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ 2019; 22: 593–604, doi: 10.1080/13696998.2019.1588738.
    » https://doi.org/10.1080/13696998.2019.1588738
  • 18
    Sukul N, Speyer E, Tu C, Bieber BA, Li Y, Lopes AA, et al. Pruritus and patient reported outcomes in non-dialysis CKD. Clin J Am Soc Nephrol 2019; 14: 673–681, doi: 10.2215/CJN.09600818.
    » https://doi.org/10.2215/CJN.09600818
  • 19
    Gregg LP, Hedayati SS. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Curr Opin Nephrol Hypertens 2020; 29: 457–464, doi: 10.1097/MNH.0000000000000629.
    » https://doi.org/10.1097/MNH.0000000000000629
  • 20
    Li PK, Garcia-Garcia G, Lui SF, Andreoli S, Fung WW, Hradsky A, et al. Kidney health for everyone everywhere-from prevention to detection and equitable access to care. Kidney Int 2020; 97: 226–232, doi: 10.1016/j.kint.2019.12.002.
    » https://doi.org/10.1016/j.kint.2019.12.002
  • 21
    Kalantar-Zadeh K, Li PK. Strategies to prevent kidney disease and its progression. Nat Rev Nephrol 2020; 16: 129–130, doi: 10.1038/s41581-020-0253-1.
    » https://doi.org/10.1038/s41581-020-0253-1
  • 22
    Kalantar-Zadeh K, Wightman A, Liao S. Ensuring choice for people with kidney failure - dialysis, supportive care, and hope. N Engl J Med 2020; 383: 99–101, doi: 10.1056/NEJMp2001794.
    » https://doi.org/10.1056/NEJMp2001794

Publication Dates

  • Publication in this collection
    30 Apr 2021
  • Date of issue
    2021

History

  • Received
    9 Dec 2020
  • Accepted
    29 Dec 2020
Associação Brasileira de Divulgação Científica Av. Bandeirantes, 3900, 14049-900 Ribeirão Preto SP Brazil, Tel. / Fax: +55 16 3315-9120 - Ribeirão Preto - SP - Brazil
E-mail: bjournal@terra.com.br